Penumbra, Inc. reported significant financial growth in its latest quarterly results, with revenues reaching $354.7 million for the three months ended September 30, 2025, a 17.8% increase from $301.0 million in the same period last year. For the nine months ended September 30, 2025, total revenue was $1.018 billion, up 15.8% from $879.1 million in the prior year. The company achieved a net income of $45.9 million for the third quarter, compared to $29.5 million in the same quarter of 2024, and a net income of $130.3 million for the nine-month period, a significant recovery from a net loss of $19.7 million in the previous year.
The increase in revenue was primarily driven by higher sales of both thrombectomy and embolization products, with thrombectomy sales rising by 15.8% to $236.4 million and embolization and access products increasing by 22.0% to $118.3 million in the third quarter. The U.S. market contributed significantly to this growth, with U.S. thrombectomy product sales increasing by 18.5%. International sales also saw a modest increase, contributing 22.5% of total revenue in the latest quarter, although this was down from 24.8% in the previous year.
Operationally, Penumbra has made strategic investments to enhance its manufacturing capabilities, including a new facility in Costa Rica, which is expected to support future growth. The company’s total assets increased to $1.744 billion as of September 30, 2025, up from $1.533 billion at the end of 2024, reflecting a strong cash position with $321.0 million in cash and cash equivalents. The company also reported a significant reduction in operating expenses, particularly in research and development, which decreased by 10% to $22.7 million, attributed to lower costs following the exit from its immersive healthcare business.
Looking ahead, Penumbra anticipates continued growth driven by its expanding product portfolio and market penetration strategies. The company has extended its share repurchase program, allowing for an additional $100 million in stock buybacks through December 2025, indicating confidence in its financial position. The management remains focused on innovation and operational efficiency to sustain its competitive edge in the medical device market, particularly in thrombectomy and embolization technologies.
About Penumbra Inc
Penumbra, Inc. develops innovative medical devices for treating vascular and neurovascular conditions, including thrombectomy, embolization, and access products. Its portfolio targets stroke, pulmonary embolism, aneurysms, and other blood vessel disorders, primarily serving healthcare providers worldwide. The company emphasizes proprietary technology, regulatory compliance, and clinical research to deliver safe, effective, and cost-efficient solutions in endovascular therapy.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.